{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:48:58Z","timestamp":1790740138428,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40265-019-01118-9","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T16:36:04Z","timestamp":1557160564000},"page":"855-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?"],"prefix":"10.1007","volume":"79","author":[{"given":"Aurelie","family":"Lenglet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fabresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9line","family":"Taupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Gomila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Drueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ndt\/gfv055","volume":"31","author":"JB Cannata-And\u00eda","year":"2016","unstructured":"Cannata-And\u00eda JB, Martin KJ. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31:541\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1118_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14740338.2018.1476487","volume":"17","author":"F Carfagna","year":"2018","unstructured":"Carfagna F, Del Vecchio L, Pontoriero G, Locatelli F. Current and potential treatment options for hyperphosphatemia. Expert Opin Drug Saf. 2018;17:597\u2013607.","journal-title":"Expert Opin Drug Saf"},{"key":"1118_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfx249","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel A-S, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017;32:870\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.ki.5001994","volume":"105","author":"IG Nikolov","year":"2006","unstructured":"Nikolov IG, Joki N, Maizel J, Lacour B, Dr\u00fceke TB, Massy ZA. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl. 2006;105:S16\u201323.","journal-title":"Kidney Int Suppl"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1525-139X.2008.00440.x","volume":"21","author":"N Marangon","year":"2008","unstructured":"Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer: are they of clinical relevance? Semin Dial. 2008;21:385\u20139.","journal-title":"Semin Dial"},{"key":"1118_CR7","first-page":"381","volume":"50","author":"BM Wilkes","year":"1998","unstructured":"Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol. 1998;50:381\u20136.","journal-title":"Clin Nephrol"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","volume":"62","author":"W Braunlin","year":"2002","unstructured":"Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002;62:611\u20139.","journal-title":"Kidney Int"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2215\/CJN.02810707","volume":"3","author":"K Caglar","year":"2008","unstructured":"Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3:61\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000302723","volume":"29","author":"AEM Stinghen","year":"2010","unstructured":"Stinghen AEM, Gon\u00e7alves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010;29:352\u20136.","journal-title":"Blood Purif"},{"key":"1118_CR11","doi-asserted-by":"crossref","unstructured":"Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE; AGE-less Study Group. Effects of sevelamer carbonate on advanced glycation end products and antioxidant\/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol. 2015;10:759\u201366.","DOI":"10.2215\/CJN.07750814"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.14740\/jocmr1803e","volume":"9","author":"C-J Lin","year":"2017","unstructured":"Lin C-J, Pan C-F, Chuang C-K, Liu H-L, Huang S-F, Chen H-H, et al. Effects of sevelamer hydrochloride on uremic toxins serum indoxyl sulfate and P-cresyl sulfate in hemodialysis patients. J Clin Med Res. 2017;9:765\u201370.","journal-title":"J Clin Med Res."},{"key":"1118_CR13","first-page":"448","volume":"22","author":"R Castro","year":"2002","unstructured":"Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M. RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia. 2002;22:448\u201355.","journal-title":"Nefrologia."},{"key":"1118_CR14","doi-asserted-by":"crossref","unstructured":"Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins. 2018;10.","DOI":"10.3390\/toxins10010033"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-013-0024-6","volume":"13","author":"A Lenglet","year":"2013","unstructured":"Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D. 2013;13:165\u201373.","journal-title":"Drugs R D."},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/01.TP.0000098905.86445.0F","volume":"76","author":"L Moberg","year":"2003","unstructured":"Moberg L, Olsson A, Berne C, Felldin M, Foss A, K\u00e4llen R, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation. 2003;76:1285\u20138.","journal-title":"Transplantation"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0165-2478(92)90007-B","volume":"31","author":"Y Hiromatsu","year":"1992","unstructured":"Hiromatsu Y, Sato M, Yamada K, Nonaka K. Inhibitory effects of nicotinamide on recombinant human interferon-gamma-induced intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial cells. Immunol Lett. 1992;31:35\u20139.","journal-title":"Immunol Lett"},{"key":"1118_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00005-008-0009-2","volume":"56","author":"R Biedro\u0144","year":"2008","unstructured":"Biedro\u0144 R, Ciszek M, Tokarczyk M, Bobek M, Kurnyta M, S\u0142ominska EM, et al. 1-Methylnicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages. Arch Immunol Ther Exp (Warsz). 2008;56:127\u201334.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jnutbio.2010.10.009","volume":"22","author":"M Lappas","year":"2011","unstructured":"Lappas M, Permezel M. The anti-inflammatory and antioxidative effects of nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human gestational tissues: implications for preterm birth. J Nutr Biochem. 2011;22:1195\u2013201.","journal-title":"J Nutr Biochem"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature11228","volume":"487","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477\u201381.","journal-title":"Nature"},{"key":"1118_CR22","doi-asserted-by":"crossref","first-page":"117864691770466","DOI":"10.1177\/1178646917704662","volume":"10","author":"LJ Hill","year":"2017","unstructured":"Hill LJ, Williams AC. Meat intake and the dose of vitamin B3\u2014nicotinamide: cause of the causes of disease transitions, health divides, and health futures? Int J Tryptophan Res IJTR. 2017;10:1178646917704662.","journal-title":"Int J Tryptophan Res IJTR."},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nchembio.1535","volume":"10","author":"W-J Lee","year":"2014","unstructured":"Lee W-J, Hase K. Gut microbiota-generated metabolites in animal health and disease. Nat Chem Biol. 2014;10:416\u201324.","journal-title":"Nat Chem Biol"},{"key":"1118_CR24","doi-asserted-by":"crossref","unstructured":"Hauser AB, Stinghen AEM, Gon\u00e7alves SM, Bucharles S, Pecoits-Filho R. A gut feeling on endotoxemia: causes and consequences in chronic kidney disease. Nephron Clin Pract. 2011;118:c165\u2013172; discussion c172.","DOI":"10.1159\/000321438"},{"key":"1118_CR25","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1093\/ndt\/gfl273","volume":"21","author":"S Gon\u00e7alves","year":"2006","unstructured":"Gon\u00e7alves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AEM, Lima EGA, et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant. 2006;21:2788\u201394.","journal-title":"Nephrol Dial Transplant"},{"key":"1118_CR26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","volume":"149","author":"E Ferramosca","year":"2005","unstructured":"Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820\u20135.","journal-title":"Am Heart J"},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1081\/JDI-65259","volume":"27","author":"K Yamada","year":"2005","unstructured":"Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail. 2005;27:361\u20135.","journal-title":"Ren Fail"},{"key":"1118_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000319850","volume":"30","author":"AB Hauser","year":"2010","unstructured":"Hauser AB, Azevedo IRF, Gon\u00e7alves S, Stinghen A, Aita C, Pecoits-Filho R. Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Blood Purif. 2010;30:153\u20138.","journal-title":"Blood Purif"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/ki.2009.403","volume":"114","author":"PP Sun","year":"2009","unstructured":"Sun PP, Perianayagam MC, Jaber BL. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl. 2009;114:S20\u20135.","journal-title":"Kidney Int Suppl"},{"key":"1118_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000111061","volume":"28","author":"R Shantouf","year":"2008","unstructured":"Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28:275\u20139.","journal-title":"Am J Nephrol"},{"key":"1118_CR31","first-page":"120","volume":"31","author":"E Karacaglar","year":"2015","unstructured":"Karacaglar E, Atar I, Altin C, Yetis B, Cakmak A, Bayraktar N, et al. The effects of niacin on inflammation in patients with non-ST elevated acute coronary syndrome. Acta Cardiol Sin. 2015;31:120\u20136.","journal-title":"Acta Cardiol Sin."},{"key":"1118_CR32","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2215\/CJN.01650211","volume":"6","author":"JF Navarro-Gonz\u00e1lez","year":"2011","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, de Fuentes MM, Donate-Correa J, Caza\u00f1a-P\u00e9rez V, Garc\u00eda-P\u00e9rez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2272\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1118_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0165-2478(97)00088-6","volume":"59","author":"M Fukuzawa","year":"1997","unstructured":"Fukuzawa M, Satoh J, Muto G, Muto Y, Nishimura S, Miyaguchi S, et al. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett. 1997;59:7\u201311.","journal-title":"Immunol Lett"},{"key":"1118_CR34","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/00365520510023341","volume":"40","author":"A Traister","year":"2005","unstructured":"Traister A, Breitman I, Bar-Lev E, Zvibel I, Harel A, Halpern Z, et al. Nicotinamide induces apoptosis and reduces collagen I and pro-inflammatory cytokines expression in rat hepatic stellate cells. Scand J Gastroenterol. 2005;40:1226\u201334.","journal-title":"Scand J Gastroenterol"},{"key":"1118_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1365-2249.2003.02031.x","volume":"131","author":"JS Ungerstedt","year":"2003","unstructured":"Ungerstedt JS, Bl\u00f6mback M, S\u00f6derstr\u00f6m T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131:48\u201352.","journal-title":"Clin Exp Immunol"},{"key":"1118_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000449096","volume":"42","author":"M Bossola","year":"2016","unstructured":"Bossola M, Di Stasio E, Sanguinetti M, Posteraro B, Antocicco M, Pepe G, et al. Serum endotoxin activity measured with endotoxin activity assay is associated with serum interleukin-6 levels in patients on chronic hemodialysis. Blood Purif. 2016;42:294\u2013300.","journal-title":"Blood Purif"},{"key":"1118_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/sdi.12515","volume":"29","author":"ZA Massy","year":"2016","unstructured":"Massy ZA, Pietrement C, Tour\u00e9 F. Reconsidering the lack of urea toxicity in dialysis patients. Semin Dial. 2016;29:333\u20137.","journal-title":"Semin Dial"},{"key":"1118_CR38","doi-asserted-by":"publisher","first-page":"e0187550","DOI":"10.1371\/journal.pone.0187550","volume":"12","author":"X Su","year":"2017","unstructured":"Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PLoS One. 2017;12:e0187550.","journal-title":"PLoS One"},{"key":"1118_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/art.20781","volume":"52","author":"JP Garg","year":"2005","unstructured":"Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290\u20135.","journal-title":"Arthritis Rheum"},{"key":"1118_CR40","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/ndt\/gfq053","volume":"25","author":"VM Brandenburg","year":"2010","unstructured":"Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25:2672\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1118_CR41","unstructured":"De Smet R, Thermote F, Lameire N, Vanholder R. Sevelamer hydrochloride (Renagel (R)) adsorbs the uremic compound indoxyl sulfate. 2003;14:206."},{"key":"1118_CR42","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA105.541854","volume":"112","author":"O Phan","year":"2005","unstructured":"Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation. 2005;112:2875\u201382.","journal-title":"Circulation"},{"key":"1118_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1365-2249.2004.02315.x","volume":"135","author":"A Soop","year":"2004","unstructured":"Soop A, Albert J, Weitzberg E, Bengtsson A, Nilsson C-G, Sollevi A. Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. Clin Exp Immunol. 2004;135:114\u20138.","journal-title":"Clin Exp Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01118-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:27:18Z","timestamp":1588634838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01118-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"6 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by an interregional Grant (PHRC IR08: 2008-004673-17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ziad A. Massy reports grants for CKD REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka, and the French Government, as well as fees and grants to charities from Astellas, Baxter, Daichii, Medice, and Sanofi-Genzyme. These sources of funding are not necessarily related to the content of the present manuscript. Tilman B. Drueke reports fees for advisor\/consultant services from Amgen, F. Hoffman-La Roche, FMC, Glaxo-Smith-Kline, KfH-Stiftung Pr\u00e4ventivmedizin, Sanofi-Genzyme, and Vifor and speaker fees from Akebia, Amgen, Astellas, Chugai, Kyowa Hakko Kirin, and Sanofi-Genzyme. Aurelie Lenglet, Nicolas Fabresse, M\u00e9line Taupin, Cathy Gomila, Sophie Liabeuf, Said Kamel, and Jean Claude Alvarez have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by a local investigational review board (CPP Nord Ouest II, Amiens, France; reference 2008-004673-17) and implemented in accordance with the ethical principles of the Declaration of Helsinki (ClinicalTrials.gov registration number NCT01011699).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}